Sustainable, plant-based alternative to retinol

ABSTRACT

After four years of research and development, French biotechnology company Core Biogenesis has introduced a next-generation alternative: Oleosome-Growth Factors, powering two biomimetic actives—Peauvita™ (Oleosome-EGF) and Peauforia™ (Oleosome-FGF-2). Through proprietary plant-based molecular farming, the company produces human-identical growth factors naturally fused into Camelina sativa seed oleosomes, creating a vegan, renewable, scalable, low impact production system. This fusion confers 8–10× greater stability, targeted dermal delivery, and accelerated visible results. In a 60-day randomized, head-to-head clinical trial against 0.3% retinol, a serum containing 1.0% Oleosome-EGF and 1.0% Oleosome-FGF-2 demonstrated superior outcomes across multiple ageing markers: wrinkle depth (-25.2% vs. -16.3%), wrinkle length (-27.2% vs. -22.2%), skin smoothness (77% improved vs. 59%), and skin brightness (significant increase vs. retinol). No irritation was reported. As consumers increasingly prioritize products that are both effective and responsible, Core Biogenesis positions its Oleosome-Growth Factors as the new benchmark in rejuvenation skin care: biomimetic, clinically proven, ethically produced, and reflective of a new era where performance, purity, and planet-conscious innovation converge. This article explores the biotechnological foundation of molecular farming, the functional advantages of oleosome delivery, and the clinical evidence positioning oleosome-delivered growth factors as a superior and sustainable alternative to retinol

Consumer expectations are shifting. Consumers correlate the appearance of radiant, healthy skin with wellness. In McKinsey’s State of Fashion Beauty 2025 Report survey, 44% of consumers defined beauty as taking care of the mind and body, with over 50% of consumers considering skin care to be a key contributor to their wellness routine, akin to physical exercise.¹